Free
Meeting Abstracts  |   September 1996
Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist
Author Notes
  • (Rabin) Medical Student.
  • (Reid, Guo, Zhang) Research Associate.
  • (Gustafsson) Visiting scholar.
  • (Maze) Professor in Anesthesiology.
  • Received from the Department of Anesthesia, Stanford University School of Medicine, and Anesthesiology Service Veterans Affairs Hospital, Palo Alto, California. Submitted for publication September 28, 1995. Accepted for publication May 3, 1996. Supported by the Medical Scholars Program, Stanford University, National Institutes of Health (GM 30232).
  • Address reprint requests to Mr. Rabin: Office of Student Affairs, Stanford University, Stanford University School of Medicine, Stanford, California 94305.
Article Information
Meeting Abstracts   |   September 1996
Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist
Anesthesiology 9 1996, Vol.85, 565-573.. doi:
Anesthesiology 9 1996, Vol.85, 565-573.. doi:
Key words: Brain: hippocampus; locus coeruleus. Sympathetic nervous system, alpha2-adrenergic agonists: dexmedetomidine. Sympathetic nervous system, catecholamines: norepinephrine. Receptors: alpha2adrenoceptor. Treatment: chronic.
THE antihypertensive action of alpha2agonists is exerted at many levels including their ability to inhibit the release of norepinephrine in both central and peripheral adrenergic pathways. This inhibitory action on norepinephrine release is referred to as their sympatholytic action.
Recent demonstrations of therapeutic indications for alpha sub 2 -adrenergic agonists have led to multiple uses of this class of drug in the perioperative period. [1] For example, alpha2-adrenergic agonists are efficacious for anxiolysis, [2] preoperative sedation, [3] and decreasing anesthetic requirements for volatile, [4] opioid, [5] and hypnotic induction agents. [6] Additionally, alpha2-adrenergic agonists minimize hemodynamic fluctuations, [7] facilitate induced hypotensive techniques, [8] decrease postoperative shivering, [3,9] decrease oxygen utilization, [10] and may even be effective in protecting against ischemic damage to the brain [11] and heart. [12] 
Because of the perceived benefit of these compounds at each stage in the surgical patient's care, we have advocated that subacute administration of alpha2agonists should encompass the entire perioperative period. [13] The regular practice of prolonged use of alpha2agonists in the management of chronic hypertension has clarified certain alterations in behavioral effects that accompany extended administration. While the beneficial antihypertensive effect is sustained for a period of years; the unwanted side effects, such as sedation, are relatively short-lived. [14] This differential sensitivity to chronic drug treatment can be explained by differences in the efficiency of signal transduction. The greater the efficiency with which a signal is transduced, the fewer the receptors that need to be activated to achieve a desired response. The most efficient responses have a built-in reserve that sustains the response even when the transduction mechanism is disrupted.
The development of tolerance is a ubiquitous biologic process in which responsiveness decreases with continuing exposure. While this has been particularly well characterized for responses mediated by adrenoceptors of the beta and alpha1subclasses, [15] little is known about responses mediated by the alpha2adrenoceptors. We recently demonstrated that tolerance develops to both the hypnotic [16] and analgesic [17] effects of alpha2agonists after chronic treatment with dexmedetomidine. Whether tolerance develops similarly for other potentially useful perioperative effects of alpha2agonists is not known. We now report on the sympatholytic and anesthetic-sparing actions of dexmedetomidine after chronic administration.
Methods
Animal Preparation
Two hundred twenty-three male Sprague-Dawley rats (weighing 250-300 g) were chosen as the experimental model after approval of the experimental protocol by the Animal Care and Use Committee at the Palo Alto Veterans Affairs Medical Center. Rat littermates were stratified to match weight distribution in the control and treated groups as closely as possible. All behavioral tests and animal deaths occurred between 9 AM and 1 PM.
Continuous Drug Administration. Rats were exposed to the same conditions that were demonstrated to induce tolerance to the hypnotic action of dexmedetomidine, an alpha2-adrenergic agonist. [16,17] Briefly, dexmedetomidine was chronically administered using Alzet osmotic minipumps (Model 2002 or 1007D Alza, Palo Alto, CA), which discharge their contents at a mean pumping rate of 0.48 plus/minus 0.02 micro liter *symbol* h sup -1. The pumps were loaded to deliver 3, 5, or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 for 7 days. The pumps were inserted subcutaneously into the dorsal thoracic region during halothane anesthesia. In the initial experiments control animals also had the osmotic pumps containing only the vehicle implanted. This group did not differ in behavioral response from sham-operated control animals. Therefore, the latter were used.
Depletion of alpha2Adrenoceptor Reserve. Depletion of alpha2adrenoceptors was produced with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), which covalently binds and permanently inactivates alpha2adrenoceptors; therefore, responsiveness to alpha2agonists is dependent on the recovery of the newly expressed receptor population. [18] This compound also is capable of rendering serotonergic and dopaminergic receptors dysfunctional via alkylation. Rats received 0.3 or 1.0 mg *symbol* kg sup -1 EEDQ subcutaneously.
Halothane Minimum Alveolar Concentration Testing. As previously described, the sensitivity to halothane was determined by measuring the MAC, which prevents a response to a supramaximal stimulus. [19] Briefly, halothane was vaporized in oxygen at a flow rate of 51 *symbol* min sup -1 and introduced into a methyl methacrylate polymer exposure chamber. The response of animals to supramaximal noxious stimulus was assessed by applying a 6" hemostat to the first ratchet position on the middle portion of the tail for 1 min. A positive response was noted if the rat moved purposefully in response to tail clamping. The individual testing for MAC was unblinded to the treatment.
Neurochemical Measurement. To measure monoamine turnover, animals received the vehicle or 10 and 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and were killed 30 min later by decapitation after narcosis induced by a 30-s exposure to carbon dioxide. The locus coeruleus (LC) was removed from each side and the hippocampus from the left side of the freshly harvested brain. Samples were sonicated in an ice cold 5% perchloric acid solution and centrifuged to precipitate proteins and membranes. The supernatant was filtered to exclude molecules exceeding 5,000 daltons. These samples were stable for up to 3 months when stored at -80 degrees Celsius. The biogenic amines were assayed with high performance liquid chromatography with electrochemical detection, as previously described. [20] 
The ratio of the concentrations of the major metabolite of a brain monoamine neurotransmitter to brain monoamine itself is used as an index of the overall turnover rate of the synaptic monoamine neurotransmitter. Underlying this ratio is the understanding that high concentrations of the monoamine neurotransmitter such as norepinephrine will reduce neuronal activity by acting as an autoregulator at presynaptic alpha2receptors. Conversely, increased concentrations of the neuronal metabolite, such as 3,4-dihydroxyphenylglycolaldehyde or 3-methoxy-4-hydroxyphenylglycol (MHPG), are associated with increased neuronal firing. The foregoing assumes that the formation and elimination of the monoamines and their metabolites are proportional to their concentrations. [21] 
Receptor Density. alpha2Receptor density was measured in the LC 4 or 24 h after EEDQ administration. Animals were killed by decapitation under carbon dioxide narcosis and the LCs (2 LCs/rat) were harvested. Tissue was homogenized in 500 micro liter ice-cold Tris, 50 mM, EDTA 0.8 mM buffer pH 7.5. After centrifugation at 500 x g (Sorvall RC-5B, rotor SS-34 rotor, Dupont, Wilmington, DE) for 5 min, the supernatants were collected and centrifuged at 44,000 x g (20 min). The pellets were then washed once with the same buffer. The final pellets were stored at -80 degrees Celsius in potassium phosphate 50 mM buffer, pH 7.65, for no longer than 3 weeks. On the day of the assay, aliquots of membranes were thawed at room temperature and resuspended in Tris 50 mM buffer, pH 7.6, containing 10 mM MgCl2. The membrane preparation was incubated for 15 min at 37 degrees Celsius and centrifuged at 44,000 x g for 20 min. This washing procedure was repeated and the final membrane pellet was resuspended in 150 micro liter 50 mM Tris-HCL, 10 mM MaCl2, 1 mM EGTA, pH 7.6 (buffer A). The binding procedures on the LC were adapted from Baron and Siegel. [22] 
Experimental Regimens
Chronic Dexmedetomidine and the Minimum Alveolar Concentration-sparing Response to Acute Dexmedetomidine. After a sham operation (naive group) or chronic (7 days) dexmedetomidine administration (5 and 10 micro gram *symbol* kg sup -1 *symbol* h sup -1), separate cohorts of rats (n = 6 - 10) were tested for their MAC-sparing response before and after intraperitoneal dexmedetomidine, 10 (only for the 10- micro gram *symbol* kg sup -1 *symbol* h sup -1 group) and 30 micro gram *symbol* kg sup -1 (the ED50, dose for MAC reduction). [19] 
Chronic Dexmedetomidine and Norepinephrine Turnover Response to Acute Dexmedetomidine. After a sham operation (naive group) or chronic (7 days) dexmedetomidine (3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1), separate cohorts (n = 7 - 8) reserved either dexmedetomidine, 10 (only for the 10- micro gram *symbol* kg sup -1 *symbol* h sup -1 group) or 30 micro gram *symbol* kg sup -1, or saline. Thirty minutes after the acute administration, animals were decapitated and norepinephrine turnover was measured in the LC and hippocampus.
Receptor Reserve and Minimum Alveolar Concentration-sparing Response to Dexmedetomidine. Twenty-four and and 72 h after 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ administration, separate cohorts of rats (n = 7) were tested for their MAC-sparing response before and after 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine.
Receptor Reserve and the Effect of Dexmedetomidine on Norepinephrine Turnover. After 0.3 and 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ administration, separate cohorts (n = 5 - 8) of rats were tested for their norepinephrine turnover response to 30 micro gram *symbol* kg sup -1 dexmedetomidine or saline at 4 h (EEDQ 1.0 mg *symbol* kg sup -1) or 24 h (EEDQ 0.3 mg *symbol* kg sup -1).
Statistics
Data are expressed as mean plus/minus SEM. The results of multiple groups were analyzed by analysis of variance followed by Fisher's post hoc test. Comparison between two groups was performed by t test for unpaired data. A P value < 0.05 was considered statistically significant.
Results
Norepinephrine Turnover and Chronic Dexmedetomidine. In the LC (Figure 1(A)), chronic administration of both dexmedetomidine doses (3 and 10 micro gram *symbol* kg sup -1 *symbol* h sup -1) fails to alter the MHPG/norepinephrine ratio. Acute administration of dexmedetomidine (30 micro gram *symbol* kg sup -1 intraperitoneal) to animals receiving chronic treatment, decreased (P < 0.05) the MHPG/norepinephrine ratio.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
×
In the hippocampus (Figure 1(B)), chronic administration of both dexmedetomidine doses (3 and 10 micro gram *symbol* kg sup -1 *symbol* h sup -1) reduces (P < 0.0001) the MHPG/norepinephrine ratio compared to naive animals. Acute administration of dexmedetomidine (30 micro gram *symbol* kg sup -1 intraperitoneal) to animals receiving chronic treatment, results in a further reduction (P < 0.05) in the MHPG/norepinephrine ratio.
Similar findings were seen in both the LC (Figure 2(A)) and the hippocampus (Figure 2(B)) after acute administration of dexmedetomidine (10 micro gram *symbol* kg sup -1 intraperitoneal) to animals receiving chronic treatment (10 micro gram *symbol* kg sup -1 *symbol* h sup -1 dexmedetomidine).
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
×
The Minimum Alveolar Concentration-sparing Effect and Chronic Dexmedetomidine. Chronic administration of both dexmedetomidine doses (5 and 10 micro gram *symbol* kg sup -1 *symbol* h sup -1) for 7 days did not alter the baseline minimum anesthetic concentration for halothane (Figure 3). Acute administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine to animals receiving chronic treatment results in a MAC-sparing effect that is similar to the response seen in the naive animals. The MAC for halothane after acute dexmedetomidine was decreased (P < 0.0001) in both the tolerant and naive groups. Analogous findings were seen after acute administration of 10 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine to animals receiving chronic dexmedetomidine treatment (10 micro gram *symbol* kg sup -1 *symbol* h sup -1).
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
×
Receptor Reserve and the Effect of Dexmedetomidine on Norepinephrine Turnover. After EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), administration 24 h before saline, basal levels of norepinephrine turnover were unaltered in the LC (Figure 4(A)) but significantly (P < 0.0001) increased in the hippocampus (Figure 4(C)). Dexmedetomidine (30 micro gram *symbol* kg sup -1 intraperitoneal), injected 24 h after EEDQ, decreased (P < 0.001) norepinephrine turnover in the hippocampus and LC. A higher dose of EEDQ (1.0 mg *symbol* kg sup -1 subcutaneous), administered 4 h before dexmedetomidine, increased (P < 0.001) basal levels of norepinephrine turnover in the hippocampus and LC (Figure 4(B and D)). Dexmedetomidine (30 micro gram *symbol* kg sup -1 *symbol* intraperitoneal) injected after this EEDQ treatment failed to decrease norepinephrine turnover. Four hours after 1.0 mg *symbol* kg sup -1 EEDQ (Table 1), there was a 96% reduction in alpha2adrenoceptor binding sites in the LC.
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
×
Table 1. Effect of N-Ethoxycarbonyl-2-Ethoxy-1,2 Dihydroquinoline (EEDQ) on alpha2-Adrenoceptor Binding Sites
Image not available
Table 1. Effect of N-Ethoxycarbonyl-2-Ethoxy-1,2 Dihydroquinoline (EEDQ) on alpha2-Adrenoceptor Binding Sites
×
Receptor Reserve and the Halothane MAC-sparing Effect of Dexmedetomidine. EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), administered 72 and 24 h before testing, did not alter the baseline MAC for halothane (Figure 5(A and B)). Dexmedetomidine's MAC-sparing effect was completely blocked in rats treated with EEDQ 24 h before acute administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. In naive rats or rats treated with EEDQ 72 h earlier, the MAC-sparing effect to acute administration of dexmedetomidine remained intact (P < 0.0001).
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
×
Treatment with EEDQ produced a dose-dependent reduction in alpha2adrenoceptor binding sites in the LC (Table 1) without affecting the binding affinity (dissociation constant). The dose-dependent reduction in alpha2adrenoceptor binding sites for alpha2adrenoceptors in the LC was reduced by 60% in rats 72 h after 0.3 mg *symbol* kg sup -1 EEDQ injection. [17] Previously, we reported that this treatment significantly attenuated the hypnotic and analgesic responses to dexmedetomidine. [17] An 80% reduction in alpha2adrenoceptor binding sites in the LC, which occurred 24 h after 0.3 mg *symbol* kg sup -1 EEDQ, was necessary to attenuate the MAC-sparing effect of dexmedetomidine.
Discussion
The sympatholytic and MAC-sparing effects of dexmedetomidine are preserved after chronic administration of the drug. Dexmedetomidine requires between 20% and 40% alpha2adrenoceptor availability in the LC to express its anesthetic-reducing effect and between 4% and 20% alpha2adrenoceptor availability to decrease norepinephrine turnover.
Norepinephrine turnover was assessed in brainstem (LC) and limbic (hippocampus) regions. The LC was selected because it is an important site for the anesthetic action of alpha2-adrenergic agonists. [23] Additionally, it is the principal noradrenergic nucleus in the mammalian CNS and a discrete area with a high density of alpha2adrenoceptors. The hippocampus, which derives all of its noradrenergic input from the LC, was chosen as an indicator of LC neuronal activity. Both intraperitoneal administration of piperoxan, an alpha2antagonist, and direct electric stimulation of the LC increase MHPG concentrations in areas in which noradrenergic innervation arise solely from the LC (i.e., cerebellum, hippocampus, and cortex). [24-26] Hence, norepinephrine turnover in the hippocampus may be reflective of other brain regions subserved by noradrenergic input from the LC.
We have shown that the central sympatholytic effect of acutely administered dexmedetomidine is sustained under the same conditions in which animals were rendered tolerant to the hypnotic and analgesic effects of alpha2agonists. One explanation for the relative resistance to desensitization may relate to a large receptor reserve for autoreceptor function. Several studies have demonstrated a large surplus of spare autoreceptors in various systems including dopaminergic, [27] serotonergic, [28] and alpha2-adrenergic. [29-31] Thus, it is possible that even if a large fraction of the alpha2autoreceptors are rendered nonfunctional, through uncoupling or internalization, the response transduced by the remaining receptors may still be intact. In animals treated with EEDQ, we demonstrated that greater than 4% and less than 20% of the alpha2-adrenoceptor population was required to produce the norepinephrine turnover effect of dexmedetomidine.
Previously, we have shown a correlation between receptor reserve and resistance to the induction of tolerance for alpha2-adrenergic responses. [17] The hypnotic response to dexmedetomidine, which has a receptor reserve of 23%, was decreased after 2 days of 3 micro gram *symbol* kg sup -1 *symbol* h sup -1 dexmedetomidine administration. In contrast, the tail-flick analgesic response, which has a 40% receptor reserve, was decreased after 7 days of 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 dexmedetomidine, and the sympatholytic effect, which has a greater than 80% receptor reserve, was unaffected after 7 days of 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 dexmedetomidine. Thus, the comparative durability of the sympatholytic response compared to the hypnotic or analgesic response can be explained by a significantly greater receptor reserve owing to more efficient coupling and transduction.
It is noteworthy that chronic administration of dexmedetomidine resulted in a significant decrease in norepinephrine turnover in the hippocampus but not the LC. This finding concurs with Rochette et al. [32] who showed that chronic clonidine fails to diminish the norepinephrine turnover, as judged by the rate of decline of norepinephrine after alpha-methyltyrosine, in the brain stem and hypothalamus, while this inhibitory effect is preserved in the rest of brain. Also, Koulu et al. [33] demonstrated that chronic dexmedetomidine does not alter norepinephrine turnover, as measured by the rate of accumulation of dopa, in brain stem nuclei including the LC.
Because we did not measure the concentration of dexmedetomidine in the different brain regions during chronic dexmedetomidine infusion, we are unable to exclude the possibility that the difference in norepinephrine turnover between the LC and the hippocampus is caused by a change in the distribution of the drug in these different brain regions. We assume, however, that similar levels are attained in the LC and hippocampus because all tissues should be at equilibrium with the central compartment after seven days of dexmedetomidine infusion. Recent studies using a similar infusion regimen revealed that plasma concentrations have stabilized by the second day of drug administration. [16] 
We should also consider the possibility that the alpha2adrenoceptor-effector mechanism in the hippocampus, but not the LC, is refractory to changes in sensitivity. Perhaps this difference in the sensitivity of the receptors is a function of their location in different brain regions. This explanation is supported by the observation that receptor reserve may be region specific. In studies with EEDQ, alpha2adrenoceptors regulating LC activity are characterized by a larger receptor reserve or are less sensitive to the influence of alkylation than are the population of alpha2adrenoceptors regulating norepinephrine utilization. [31] Moreover, regional variation in receptor sensitivity may be due to different subtypes of the alpha2receptor, [34] each with their respective intrinsic properties. This supposition is supported by the finding that chronic treatment with norepinephrine differentially downregulates alpha sub 2A and alpha2C-adrenoceptor subtypes. [35] 
Anesthetic Requirements and Chronic Dexmedetomidine Infusion
Chronic dexmedetomidine infusion neither changed the MAC for halothane nor norepinephrine turnover in the LC. This lack of effect may be causally related. Initial theories maintained that the MAC for anesthesia reflected the summation of changes in many systems, including the noradrenergic system. [36] More recent hypotheses have asserted that alterations in neurotransmission in discrete brain regions, as opposed to a widespread depression of neurotransmission, are responsible for the dose of drug required to produce the anesthetic state. This idea was supported by the demonstration that both cyclopropane and halothane significantly and selectively changed neurotransmitter content in a few brain regions. [37] Consonant with this hypothesis was evidence showing the regional specificity of metabolic changes, namely cerebral glucose utilization, induced by anesthetic agents. [38,39] Both of the aforementioned studies note that the LC is one of the few discrete brain regions with significant, distinctive changes in neurotransmitter content and metabolic activity after halothane anesthesia.
Studies linking the LC and volatile anesthetics are further supported by a substantial body of evidence implicating noradrenergic neurons in the modulation of anesthetic requirements. Depletion of monoamines with central neurotoxins [19,40] and elevation of central amine levels with release enhancers, dextroamphetamine [41] or cocaine, [42] have produced corresponding decreases and increases in anesthetic potency. Therefore, it is expected that the absence of change in the MAC for anesthesia would be accompanied by unaltered norepinephrine turnover in the LC. The change in norepinephrine turnover that was noted in the hippocampus would not be expected to change MAC for anesthesia because this region has been physiologically linked to memory but not to consciousness. [43] Other sites in the central nervous system that have been suggested as possible sites for volatile anesthetic action include the spinal cord, [44] although the LC remains an important candidate site for the MAC-sparing effect, if only because of its role on the hypnotic [45,46] and analgesic [47] actions of alpha2-adrenergic agonists.
Analogous to the sympatholytic effect, the anesthetic-sparing effect of acutely administered dexmedetomidine was preserved in animals rendered tolerant to the hypnotic effect of the drug by chronic administration. [16] The comparatively refractory nature of dexmedetomidine's MAC-sparing effect may be explained by the existence of spare receptors: transduction of this behavioral response requires a relatively small fraction of the alpha2receptor population, less than 40% in the LC, such that it is unaffected by the reduction in receptor reserve elicited by chronic drug administration. Thus, the refractory quality of dexmedetomidine's MAC-sparing effect may be elucidated by the empirically established link between halothane anesthesia and neuronal activity in the LC, a discrete brain region with an unusual abundance of spare alpha2-adrenergic receptors. [31] 
In summary, both the sympatholytic and MAC-sparing responses dexmedetomidine persist in rats rendered tolerant to the hypnotic and analgesic properties of dexmedetomidine. While this may be partially attributed to differences in receptor subtypes that mediate these responses, it is significant that there are large differences in receptor coupling and transduction for the individual responses. The result of this is that chronic treatment with alpha2agonists will cause efficacy to change for some but not all responses.
REFERENCES
Maze M, Tranquilli W: alpha sub 2 adrenoceptor agonists: Defining the role in clinical anesthesia. ANESTHESIOLOGY 1991; 74:581-605.
Uhde T, Stein M, Vittone B, Siever L, Boulenger J, Klein E, Mellman T: Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989; 46:170-7.
Flacke J, Bloor B, Flacke W, Wong D, Dazza S, Stead S, Laks H: Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. ANESTHESIOLOGY 1987; 67:11-9.
Aho M, Lehtinen A-M, Erkola O, Kallio A, Korttile K: The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy. ANESTHESIOLOGY 1991; 74:997-1002.
Ghignone M, Quintin L, Duke P, Kehler C, Calvillo O: Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. ANESTHESIOLOGY 1986; 64:36-42.
Aantaa R, Kanto J, Scheinin M, Kallio A, Scheinin H: Dexmedetomidine, an alpha sub 2 adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. ANESTHESIOLOGY 1990; 73:230-5.
Ghignone M, Calvillo O, Quintin L: Anesthesia and hypertension: The effect of clonidine on preoperative hemodynamics and isoflurane requirements. ANESTHESIOLOGY 1987; 67:3-10.
Woodcock T, Millar R, Dixon F, Prys-Roberts C: Clonidine premedication for isoflurane induced hypotension. Br J Anaesth 1988; 60:388-94.
Marshall H, Stoner H: Catecholaminergic alpha receptors and shivering in the rat. J Physiol (Lond) 1979; 292:27-34.
Quintin L, Viale J, Annat G, Hipen J, Butin E, Cottet-Emard J, Levron J, Bussery D, Motin J: Oxygen uptake after major abdominal surgery: Effect of clonidine. ANESTHESIOLOGY 1991; 74:236-41.
Payen D, Quintin L, Plaisance P, Chiron B, Lhoste F: Head injury: Clonidine decreases plasma catecholamines. Crit Care Med 1990; 18:392-5.
Talke PO, Mangano DT, Li J, Hollenberg M, Jain U: Effect of dexmedetomidine on myocardial ischemia in vascular surgery patients (abstract). ANESTHESIOLOGY 1993; 79:A60.
Segal I, Jarvis D, Duncan S, Shite P, Maze M: Clinical efficacy of transdermal clonidine during the perioperative period. ANESTHESIOLOGY 1991; 74:220-5.
Ferder L, Inserra F, Medina, F: Safety aspects of long-term antihypertensive therapy (10 years) with clonidine J Cardiovasc Pharmacol 1987; 10(suppl 12):S104-8.
Sibley D, Benovic J, Caron M, Lefkowitz R: Regulation of transmembrane signaling by receptor phosphorylation. Cell 1987; 48:913-22.
Reid K, Hayashi Y, Guo T-Z, Correa-Sales C, Nacif-Coelho C, Maze M: Chronic administration of an alpha sub 2 adrenergic agonist desensitizes rats to the anesthetic effects of dexmedetomidine. Pharmacol Biochem Behav 1994; 47:171-5.
Hayashi Y, Guo T-Z, Maze M: Desensitization to the behavioral effects of alpha sub 2 adrenergic agonists in rats. ANESTHESIOLOGY 1995; 82:954-62.
Meller E, Goldstein M, Friedhoff AJ, Schweitzer JW: N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): A new tool to probe CNS receptor function. Adv Exp Med Biol 1988; 235:121-36.
Segal I, Vickery R, Walton J, Doze V, Maze M: Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha sub 2 adrenergic receptor. ANESTHESIOLOGY 1988; 69:818-23.
Matsumoto M, Zornow MH, Rabin BC, Maze M: The alpha sub 2 adrenergic agonist, dexmedetomidine, selectively attenuates iscemia-induced increases in striatal norepinephrine concentrations. Brain Res 1993; 627:325-9.
Smythe GA, Bradshaw JE, Niving RF: Hypothalamic monoamine control of stress-induced adrenocorticotropin release in the rat. Endocrinology 1983; 113:1062-71.
Baron BM, Siegel BW: p-[sup 125 Iodine]iodoclonidine, a novel radiolabeled agonist for studying central alpha sub 2 adrenergic receptors. Mol Pharmacol 1990; 38:348-56.
Correa-Sales C, Rabin B, Maze M: A hypnotic response to dexmedetomidine, an alpha sub 2 agonist, is mediated in the locus coeruleus in rats. ANESTHESIOLOGY 1992; 76:899-905.
Jones B, Moore R: Ascending projections of the locus coeruleus in the rat. II, Autoradiographic study. Brain Res 1977; 127:25-53.
Bowden DM, German DC, Poynter WD: An autoradiographic,semistereotaxic mapping of major projections from locus coeruleus and adjacent nuclei in macaca mulatta. Brain Res 1978; 145:257-76.
Crawley J, Mass J, Roth R: Biochemical evidence for simultaneous activation of multiple locus coeruleus efferents. Life Sci 1980; 26:1373-8.
Meller E, Helmer-Matyjek E, Bohmaker K, Adler C, Friedgoff A Goldstein M: Receptor reserve at striatal dopamine autoreceptors: Implications for selectivity of dopamine agonists. Eur J Pharmacol 1986; 123:311-4.
Bohmaker K, Eison A, Yocca F, Meller E: Comparative effects of chronic 8-OH-DPAT, gepirone and ipsapirone treatment on the sensitivity of somatodendritic 5-HT sub 1A autoreceptors. Neuropharmacology 1993; 32:527-34.
Lenox R, Ellis J, Riper D, Ehrlich Y: Alpha sub 2 -adrenergic receptor-mediated regulation of adenylate cyclase in the intact human platelet. Mol Pharmacol 1984; 27:1-9.
Adler C, Meller E, Goldstein M: Receptor reserve at the alpha sub 2 -adrenergic receptor in the rat cerebral cortex. J Pharmacol Exp Ther 1987; 240:508-14.
Engberg E, Eriksson E: Effects of alpha sub 2 -adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 343:472-7.
Rochette L, Bralet A-M, Bralet J: Effect of chronic clonidine treatment on the turnover of noradrenaline and dopamine in various regions of the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 319:40-2.
Koulu M, Pesonen U, Virtanen R: Chronic dexmedetomidine, a selective alpha sub 2 agonist, decreases serotonin but not noradrenaline turnover in rat brainstem nuclei. Eur J Pharmacol 1990; 176:151-7.
Bylund DB: Subtypes of alpha sub 2 -adrenoceptors: Pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9:356-61.
Shreve P, Toews M, Bylund D: alpha sub 2A - and alpha sub 2C -Adrenoceptor subtypes are differentially down-regulated by norepinephrine. Eur J Pharmacol 1991; 207:275-6.
Shim C, Andersen N: Minimal alveolar concentration (MAC) and dose-response curves in anesthesia. ANESTHESIOLOGY 1972; 36:146-51.
Roizen M, Kopin I, Thoa N, Zivin J, Muth E, Jacobowitz D: The effect of two anesthetic agents on norepinephrine and dopamine in discrete brain nuclei, fiber tracts, and terminal regions of the rat. Brain Res 1976; 110:515-22.
Shapiro H, Greenberg J, Reivich M, Ashmead G, Sokoloff L: Local cerebral glucose uptake in awake and halothane-anesthetized primates. ANESTHESIOLOGY 1978; 48:97-103.
Peschanski M, Villanueva L, Le Bars D, Bernard J-F: Differential metabolic activity in the brain during deep halothane anesthesia. A qualitative study (sup 3 Hydrogen)deoxyglucose. Neuroscience Letters 1986; 71:1-6.
Mueller R, Smith R, Spruill W, Breese G: Central monoaminergic neuronal effects on minimum alveolar concentration (MAC) of halothane and cyclopropane in rats. ANESTHESIOLOGY 1975; 42:143-52.
Johnson R, Way W, Miller R: Alteration of anesthetic requirement by amphetamine. ANESTHESIOLOGY 1972; 36:357-63.
Stoelting R, Creasser C, Martz R: Effect of cocaine administration on halothane MAC in dogs. Anesth Analg 1975; 54:422-4.
Sprick U: Functional aspects of the involvement of the hippocampus in behavior and memory functions. Behav Brain Res 1995; 66(1-2):61-4.
King BS, Rampil IJ. Anesthetic depression of spinal motor neurons may contribute to lack of movement in response to noxious stimuli. ANESTHESIOLOGY 1994; 81:1484-92.
de Sarro G, Ascioti C, Froio F, Libri V, Nistico G: Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha sub 1 and alpha sub 2 adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987; 90:675-85.
Correa-Sales C, Rabin B, Maze M: A hypnotic response to dexmedetomidine, an alpha sub 2 agonist, is mediated in the locus coeruleus in rats. ANESTHESIOLOGY 1992; 76:948-52.
Guo T-Z, Buttermann AE, Jiang J-Y, Maze M: Dexmedetomidine injection into the locus coeruleus produces analgesia. ANESTHESIOLOGY 1996;84:873-81.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
Figure 1. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 3 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 30 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.0001 (hippocampus) and P < 0.005 (locus coeruleus) *P < 0.05 compared with basal state (Fisher test) (section)P < 0.0001 compared with naive group. n = 7-8 per group.
×
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
Figure 2. Effect of chronic dexmedetomidine administration on norepinephrine turnover plus/minus acute dexmedetomidine in the (A) locus coeruleus and (B) hippocampus. Rats were implanted with osmotic pumps set to deliver 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, rats were administered 10 micro gram *symbol* kg sup -1 dexmedetomidine intraperitoneally and the turnover of norepinephrine was determined. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.05 (hippocampus) and P < 0.05 (locus coeruleus) compared with basal state (Fisher test) (section)P < 0.05 compared with naive group. n = 7-8 per group.
×
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
Figure 3. Effect of chronic dexmedetomidine administration on the minimum alveolar concentration-sparing effect to halothane. Rats were implanted with osmotic pumps set to deliver 5 or 10 micro gram *symbol* kg sup -1 *symbol* h sup -1 (tolerant groups) or sham-operated (naive group). On the 7th day, the minimum alveolar concentration for halothane was determined twice in each animal, before and after administration of either 10 or 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.05 compared with basal state (paired t test). n = 7-8 per group.
×
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
Figure 4. Dexmedetomidine-induced changes in norepinephrine turnover after treatment with two doses of N-ethoxycarbonyl-2-ethoxy-1,2 dihydroquinoline (EEDQ). (A) locus coeruleus 24 h after treatment with EEDQ (0.3 mg *symbol* kg sup -1 subcutaneous), (B) locus coeruleus 4 h after treatment with EEDQ1.0 mg *symbol* kg sup -1 subcutaneous EEDQ, (C) hippocampus 24 h after treatment with 0.3 mg *symbol* kg sup -1 subcutaneous EEDQ, and (D) hippocampus 4 h after treatment with 1.0 mg *symbol* kg sup -1 subcutaneous EEDQ. After EEDQ treatment, rats were injected with saline or dexmedetomidine30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as a percentage of control animals normalized to 100%. ANOVA: P < 0.001 *P < 0.001 compared with animals injected acutely with saline (Fisher test) (section)P <0.001 compared with non-EEDQ injected group. n = 5-8 per group.
×
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
Figure 5. The halothane minimum alveolar concentration-sparing effect of dexmedetomidine after treatment with N-ethoxycarbonyl-2-ethoxy-1,2dibydroquinoline. In separate groups of rats, the minimum alveolar concentration for halothane was determined (A) 72 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxycarbonyl-2-ethoxy-1,2dihydroquinoline and (B) 24 h after treatment with 0.3 mg *symbol* kg subcutaneous N-ethoxy-carbonyl-2-ethoxy-1,2dibydroquinoline. The minimum alveolar concentration was determined twice in each animal, before and after administration of 30 micro gram *symbol* kg sup -1 intraperitoneal dexmedetomidine. Data are expressed as means plus/minus SEM. *P < 0.0001 compared with basal state (paired t test). n = 7 per group.
×
Table 1. Effect of N-Ethoxycarbonyl-2-Ethoxy-1,2 Dihydroquinoline (EEDQ) on alpha2-Adrenoceptor Binding Sites
Image not available
Table 1. Effect of N-Ethoxycarbonyl-2-Ethoxy-1,2 Dihydroquinoline (EEDQ) on alpha2-Adrenoceptor Binding Sites
×